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EDITORIAL
Heart rate decrease: A new paradigm in the
treatment of heart failure. Insights from the SHIFT
study
Réduction de la fréquence cardiaque : un nouveau paradigme dans le
traitement de l’insufﬁsance cardiaque. Implications de l’étude SHIFT
KEYWORDS
not known until the recent publication of the Systolic heart
failure treatment with If inhibitor ivabradine trial (SHIFT)
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Heart rate is recognized as a strong predictor of mortal-
ity and morbidity in the general population as well as in a
broad spectrum of cardiovascular disorders including hyper-
tension, myocardial infarction, coronary artery disease and
chronic heart failure with reduced ejection fraction as well
as heart failure with preserved ejection fraction [1—6]. The
underlying mechanism of the deleterious effect of elevated
heart rate remains partially unknown. However, beyond an
increase in myocardial oxygen consumption, elevated heart
rate is associated in experimental models with vascular
oxidative stress, endothelial dysfunction, acceleration of
atherogenesis and coronary plaque instability [7].In heart failure, beta-blocker therapy is associated with
a marked improvement in outcomes, which seems propor-
tional to the magnitude of heart rate reduction and might
involve a reverse remodelling effect [8,9]. However, since
beta-blockers have multiple mechanisms of action, it was
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doi:10.1016/j.acvd.2011.01.001hether a pure heart rate reduction obtained by a brady-
ardic agent devoid of any other signiﬁcant pharmacological
roperties — the If channel blocker ivabradine— would be
eneﬁcial in this condition.
ey lessons from SHIFT
n a population of 6558 chronic heart failure patients with
educed ejection fraction, in sinus rhythm and elevated
eart rate greater or equal to 70 beats per minute (bpm),
he addition of ivabradine 5mg to 7.5mg bid on top of
he best possible recommended therapy brings additional
eneﬁt and reduces signiﬁcantly the occurrence of the pri-
ary composite, cardiovascular mortality or heart failure
ospitalizations, by 18%. This effect is driven mainly by a
igniﬁcant reduction in heart failure hospitalizations (—26%)
nd heart failure deaths (—26%) [10].
Heart rate is not only a risk marker but also a risk factor in
eart failure: the risk of cardiovascular outcomes increases
ith heart rate and every 5 bpm increase in baseline heart
ate is associated with a 16% increase in the risk of the pri-
ary outcome in the placebo arm. The beneﬁcial effect
f ivabradine is solely accounted for by heart rate reduc-
ion since the adjustment for change in heart rate at 28
ays in the active arm neutralizes the effect of the drug for
ubsequent outcomes [11].
The minimal risk is observed in patients who reach a
arget heart rate less than 60 bpm at 28 days.
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mplications and questions
HIFT suggests that a greater attention should be paid to
simple biomarker, resting heart rate, which is a power-
ul predictor of outcomes in chronic heart failure. Indeed,
pidemiological studies suggest that despite the dissemina-
ion of beta-blocker therapy, heart rate remains elevated
> 70 bpm) in a substantial proportion of patients [12,13].
his is at least partially the result of under dosage of this
herapy as a result of poor tolerance or lack of awareness of
he recommended target dose in real-life conditions.
It might be tempting then to substitute beta-blocker
herapy by ivabradine given the overall good tolerability of
his drug. However, SHIFT provides no insight on this ques-
ion since an overwhelming majority of patients included
n this trial were on beta-blocker therapy (90%). Therefore,
he only scientiﬁcally valid conclusion that can be drawn
rom SHIFT is that in chronic heart failure patients treated
ith beta-blockers who remain with an elevated heart rate
or any reason, ivabradine should be considered on top of
heir existing therapy in order to improve outcomes and
articularly heart failure events.
Of note, the magnitude of the effect was similar in the
mall subgroup not receiving a beta-blocker to that observed
n the rest of the population, suggesting that in chronic heart
ailure patients intolerant to beta-blockers, reducing heart
ate by ivabradine brings a similar beneﬁt to that observed
n other patients and could be considered as an alternative.
ould co-prescription of beta-blockers at
ow/medium dose with ivabradine be
referable to an up-titration of
eta-blockers?
here is no clear answer to this important practical ques-
ion from the SHIFT results since more than 50% of the
atients enrolled in this trial were taking at least half
f the target recommended dose and 26% were at target
ose. The investigators were repeatedly encouraged by the
xecutive committee to provide the best possible therapy
o their patients including beta-blocker target dose. The
HIFT results should therefore be interpreted as heart rate
eduction by ivabradine bringing an incremental beneﬁt in
atients with elevated heart rate who are unlikely to toler-
te maximal doses of beta-blockers, as frequently observed
n daily practice.
an the results be generalized to the
verall heart failure population?
atients included in SHIFT were selected on the basis of
igh resting heart rate, sinus rhythm and reduced ejec-
ion fraction. In addition, the proportion of elderly patients
as limited. The effects of ivabradine cannot therefore be
eneralized to the overall heart failure population and in
articular to patients in atrial ﬁbrillation or with heart fail-
re and preserved ejection fraction.Editorial
s there an optimal heart rate in chronic
eart failure?
ince the analysis of the relationship between heart rate
eduction achieved at 28 days with ivabradine and subse-
uent outcomes suggests that patients with the lowest risk
eached a heart rate less than 60 bpm, it is reasonable to rec-
mmend this target in daily practice, when tolerated. There
s no information available on the potential beneﬁt/harm of
owering further heart rate although it should be reminded
hat cardiac output is the product of heart rate and stroke
olume so that very low heart rates result in a signiﬁcant
ecrease in cardiac output and therefore in reduced oxygen
elivery to the body.
hat is the underlying mechanism for the
eneﬁt observed with heart rate
eduction?
ome beta-blocker studies suggest that one possible mech-
nism underlying the beneﬁt of heart rate reduction is
everse remodelling with improvement in cardiac function
9]. Whether this applies to ivabradine is addressed in a
peciﬁc cardiac function echo-Doppler substudy, which is
urrently being analysed.
onclusion
HIFT, a large outcome trial, brings new insight into the
ole of heart rate as a risk factor in chronic heart failure
nd on the importance of heart rate reduction —when ele-
ated— in order to improve outcomes in heart failure in sinus
hythm and with reduced ejection fraction. The addition of
pure bradycardic agent, ivabradine, to the best possible
ecommended therapy provides a signiﬁcant improvement
n cardiovascular outcomes in this population and should be
onsidered to reduce further the burden of chronic heart
ailure and the risk related to this disorder.
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